MIM
SGMT icon

MTM Investment Management’s Sagimet Biosciences SGMT Stock Holding History

MTM Investment Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.77K Buy
+1,870
New +$10.4K ﹤0.01% 526

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MTM Investment Management's SGMT Position: Q1 2026 in Review

MTM Investment Management opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 1,870 shares worth $9.77K. The stake represents ﹤0.01% of the portfolio and ranks #526 among its holdings.

88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • MTM Investment Management held 1,870 shares of Sagimet Biosciences worth $9.77K as of Q1 2026.
  • Sagimet Biosciences was a new MTM Investment Management position in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of MTM Investment Management's portfolio in Q1 2026, its #526 holding.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on MTM Investment Management's 13F filing for Q1 2026, filed 6 May 2026.